COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies

References

• Rota PA, Oberste MS, Monroe SS, et al. Characterization of a Novel Coronavirus associated with severe acute respiratory syndrome. Science. 2003;300(5624):1394–1399.
   PubMed Web of Science ®Google Scholar
• Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on Coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11.
   PubMed Web of Science ®Google Scholar
• Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278–280.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Valent F, Pasut E, et al. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. 2020;87(5):439–443. doi:.
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395(10223):470–473.
   PubMed Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971.
   PubMed Web of Science ®Google Scholar
• Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun. 2004;314(1):235–241.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. bioRxiv. 2020. 2020.01.26.919985.
   Google Scholar
• Zou Z, Yan Y, Shu Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5(1):3594.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Ingegnoli F, De Lucia O, et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev. 2020;19(5):102523.
   PubMed Web of Science ®Google Scholar
• Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020. 2020.02.06.20020974.
   Google Scholar
• Chen F, Liu ZS, Zhang FR, et al. [First case of severe childhood novel coronavirus pneumonia in China]. Zhonghua Er Ke Za Zhi. 2020;58(0):E005.
   PubMedGoogle Scholar
• Marotto D, Sarzi-Puttini P. What is the role of rheumatologists in the era of COVID-19? Autoimmun Rev. 2020;19(6):102539–102539.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Yildiz H, Van Den Neste E, P. Defour J, et al. Adult haemophagocytic lymphohistiocytosis: a review. Int J Med. 2020;21(14):11.
   Google Scholar
• Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. The Lancet. 2014;383(9927):1503–1516.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still’s disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmun Rev. 2015;14(5):429–437.
   PubMed Web of Science ®Google Scholar
• Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–770.
   PubMed Web of Science ®Google Scholar
• Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020. 2020.02.10.20021832.
   Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615–633.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology. 2003;42(1):6–13.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–442.
   PubMed Web of Science ®Google Scholar
• Elemam NM, Hannawi S, Maghazachi AA. Role of chemokines and chemokine receptors in rheumatoid arthritis. Immunotargets Ther. 2020;9:43–56.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679–707.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(01):88–96.
   PubMedGoogle Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–1874.
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. The American journal of managed care. Suppl 9. 2007;13:S237–S251.
   Google Scholar
• Mathew AJ, Ravindran V. Infections and arthritis. Best Pract Res Clin Rheumatol. 2014;28(6):935–959.
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Smyk DS, Invernizzi P, et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013;12(7):726–740.
   PubMed Web of Science ®Google Scholar
• Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–827.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–141.
   PubMed Web of Science ®Google Scholar
• Li S, Yu Y, Yue Y, et al. Microbial infection and rheumatoid arthritis. J Clin Cell Immunol. 2013;4(6):174.
   PubMedGoogle Scholar
• Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52(1):53–61.
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50(1):124–131.
   PubMed Web of Science ®Google Scholar
• Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):353–361.
   PubMed Web of Science ®Google Scholar
• Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68.
   PubMed Web of Science ®Google Scholar
• Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology. 2013;52(10):1809–1817.
   PubMed Web of Science ®Google Scholar
• Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–792.
   PubMed Web of Science ®Google Scholar
• Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247–250.
   PubMed Web of Science ®Google Scholar
• Kłodziński Ł, Wisłowska M. Comorbidities in rheumatic arthritis. Reumatologia. 2018;56(4):228–233.
   PubMedGoogle Scholar
• Liang X, Shi L, Wang Y. The association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates. J Infect. 2020;81(3):e44–e60.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334.
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830.
   PubMed Web of Science ®Google Scholar
• Han C, Robinson DW, Jr., Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–2172.
   PubMed Web of Science ®Google Scholar
• Mazucanti CH, Egan JM. SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? Immun Ageing. 2020;17:21.
   PubMed Web of Science ®Google Scholar
• Zhang J-J, Dong X, Cao Y-y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–1741.
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Ye M, Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55(7):2132–2139.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;S0163-4453(20):30234–30236.
   Google Scholar
• Karlson EW, Lee IM, Cook NR, et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 1999;42(5):910–917.
   PubMed Web of Science ®Google Scholar
• van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69(8):1554–1561.
   PubMed Web of Science ®Google Scholar
• Mahdi H, Fisher BA, Källberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009;41(12):1319–1324.
   PubMed Web of Science ®Google Scholar
• Anzilotti C, Merlini G, Pratesi F, et al. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol. 2006;33(4):647–651.
   PubMed Web of Science ®Google Scholar
• Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22(9):1653–1656.
   PubMed Web of Science ®Google Scholar
• Peeva E, Venkatesh J, Michael D, et al. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother. 2004;58(5):310–319.
   PubMed Web of Science ®Google Scholar
• Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther. 2009;11(5):252–252.
   PubMed Web of Science ®Google Scholar
• Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. [10.3389/fpubh.2020.00152].Front Public Health. 2020;8:152
   PubMed Web of Science ®Google Scholar
• Makol A, Crowson CS, Wetter DA, et al. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology. 2014;53(5):890–899.
   PubMed Web of Science ®Google Scholar
• Castelnovo L, Capelli F, Tamburello A, et al. Symmetric cutaneous vasculitis in COVID-19 pneumonia. J Eur Acad Dermatol Venereol. 2020;34(8):16589.
   Web of Science ®Google Scholar
• de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P, et al. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol. 2020;34(10):e566–e568.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu J, Tan B. Hypercoagulation in patients with rheumatoid arthritis correlates with activation of Act1/NF-kb signaling pathway. J Rheum Dis Treat. 2015;1(4):024.
   Google Scholar
• Ichikawa Y, Hoshina Y, Horiki T, et al. Molecular markers of coagulation and fibrinolysis as indicators for the disease activity of rheumatoid arthritis. Jpa J Rheumatol. 1997;7(3):173–181.
   Google Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337–342.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv. 2020. 2020.02.29.20029520.
   Google Scholar
• Li F, Xu J, Zheng J, et al. Association between interleukin-6 gene polymorphisms and rheumatoid arthritis in Chinese Han population: a case-control study and a meta-analysis. Sci Rep. 2014;4:5714.
   PubMed Web of Science ®Google Scholar
• Kirtipal N, Bharadwaj S. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans. J Biomol Struct Dyn. 2020:1–3.
   PubMed Web of Science ®Google Scholar
• Perricone C, Conigliaro P, Ciccacci C, et al. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. Clin Exp Rheumatol. 2020;38(3):580–32452345.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Ruscitti P, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524.
   PubMed Web of Science ®Google Scholar
• Smith AC, Thomas E, Snoswell CL, et al. Telehealth for global emergencies: implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare. 2020;26(5):309–313.
   PubMed Web of Science ®Google Scholar
• Bae S, Kim SR, Kim M-N, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021;107(5):373–380.
   PubMed Web of Science ®Google Scholar
• Lim S, Bae JH, Kwon H-S, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71–72.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. 2020;47(8):1296–1296.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Ko CH, Wang JL, et al. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019;21(1):211.
   PubMed Web of Science ®Google Scholar
• Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1):e000935.
   PubMed Web of Science ®Google Scholar
• Blumentals WA, Arreglado A, Napalkov P, et al. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.
   PubMed Web of Science ®Google Scholar
• Koetz K, Bryl E, Spickschen K, et al. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 2000;97(16):9203–9208.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Masala IF, di Franco M, et al. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(4):323–330.
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3): 4174.
   Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866.
   PubMed Web of Science ®Google Scholar
• Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–668.
   PubMed Web of Science ®Google Scholar
• Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988–990.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol. 2020;72(10):1600–1606.
   PubMed Web of Science ®Google Scholar
• Zen M, Fuzzi E, Astorri D, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502.
   PubMed Web of Science ®Google Scholar
• Stradner MH, Dejaco C, Zwerina J, et al. Rheumatic musculoskeletal diseases and COVID-19 a review of the first 6 months of the pandemic. Front Med. 2020;7:562142.
   Web of Science ®Google Scholar
• D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26(6):832–834.
   PubMed Web of Science ®Google Scholar
• Cheng C, Li C, Zhao T, et al. COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol. 2020;39(7):2025–2029.
   PubMed Web of Science ®Google Scholar
• Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384–391.
   PubMed Web of Science ®Google Scholar
• D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156–1162.
   PubMed Web of Science ®Google Scholar
• Serling-Boyd N, D’Silva KM, Hsu TYT, et al. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. 2020;annrheumdis-2020-219279.
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):102.
   Web of Science ®Google Scholar
• Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• Stower H. Lopinavir-ritonavir in severe COVID-19. Nat Med. 2020;26(4):465–465.
   Web of Science ®Google Scholar
• World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. 2020. p. 21–21.
   Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel Coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Horby PW, Mafham M, Bell JL, et al. ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2020;396(10259):1345–1352.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. 2020; [cited 2021 Mar 22]. Available from: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19.
   Google Scholar
• Benucci M, Damiani A, Infantino M, et al. Old and new antirheumatic drugs for the treatment of COVID-19. Joint Bone Spine. 2020;87(3):195–197.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Semerano L, Benucci M, et al. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020;87(3):191–193.
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ. 1998;316(7134):811–818.
   PubMedGoogle Scholar
• Dennison EM, Cooper C. Corticosteroids in rheumatoid arthritis. BMJ. 1998;316(7134):789–790.
   PubMedGoogle Scholar
• Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biolog Regul Homeos Ag. 2020;34(3):1–5.
   Google Scholar
• Selvaraj V, Dapaah-Afriyie K, Finn A, et al. Short-term dexamethasone in SARS-CoV-2 patients. Rhode Island Med J. 2020;103(6):39–43.
   Google Scholar
• The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — Preliminary Report. New Eng J Med. 2020;384:693–704.
   PubMed Web of Science ®Google Scholar
• Devaux CA, Rolain J-M, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;2013/02/0123(2):300–302.
   PubMed Web of Science ®Google Scholar
• Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig g model. J Gen Virol. 2015;96(12):3484–3492.
   PubMed Web of Science ®Google Scholar
• Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine. 2017;24:189–194.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.
   PubMed Web of Science ®Google Scholar
• Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6(2):67–69.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.
   PubMed Web of Science ®Google Scholar
• Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172(12):819–821.
   PubMed Web of Science ®Google Scholar
• Guastalegname M, Vallone A. Could chloroquine/hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? Clin Infect Dis. 2020;71(15):888–889.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
   PubMed Web of Science ®Google Scholar
• Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int. 2020;40(5):825–826.
   PubMed Web of Science ®Google Scholar
• van den B, Be Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24(1):55–60.
   PubMed Web of Science ®Google Scholar
• Han J, Zhou Q, Li X, et al. Novel function of hydroxychloroquine: down regulation of T follicular helper cells in collagen-induced arthritis. Biomed Pharmacother. 2018;97:838–843.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–2502.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Y, Agostinis P, et al. Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis. 2020;11(7):512.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041–2052.
   PubMed Web of Science ®Google Scholar
• The Pharmaceutical Journal. Down, but not out: hydroxychloroquine could still have a role against COVID-19. 2020.
   Google Scholar
• Monti M, Vertogen B, Masini C, et al. Hydroxychloroquine as prophylaxis for COVID-19: a review. Front Pharmacol. 2020;11:2035.
   Web of Science ®Google Scholar
• Gentry CA, Humphrey MB, Thind SK, et al. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020;2(11):e689–e697.
   PubMedGoogle Scholar
• Konig MF, Kim AHJ, Scheetz MH, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020;79(10):1386–1388.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–818.
   PubMed Web of Science ®Google Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–1988.
   PubMed Web of Science ®Google Scholar
• Hu B, Zeng L-P, Yang X-L, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017;13(11):e1006698.
   PubMed Web of Science ®Google Scholar
• Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020;31(7):961–964.
   PubMed Web of Science ®Google Scholar
• Rizk JG, Kalantar-Zadeh K, Mehra MR, et al. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020;80(13):1267–1292.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484.
   PubMedGoogle Scholar
• Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603–e612.
   PubMedGoogle Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24–31.
   PubMed Web of Science ®Google Scholar
• Rosas I, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 Pneumonia. medRxiv. 2020. 2020.08.27.20183442.
   Google Scholar
• Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32–40.
   PubMed Web of Science ®Google Scholar
• Samaee H, Mohsenzadegan M, Ala S, et al. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int Immunopharmacol. 2020;89(Pt A):107018–107018.
   PubMed Web of Science ®Google Scholar
• Wang J, Bansal AT, Martin M, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. 2013;13(3):235–241.
   PubMed Web of Science ®Google Scholar
• Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, et al. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res. 2016;111:264–271.
   PubMed Web of Science ®Google Scholar
• Jiménez Morales A, Maldonado-Montoro M, Martínez de la Plata JE, et al. FCGR2A/FCGR3A Gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis. J Clin Pharmacol. 2019;59(4):517–531.
   PubMed Web of Science ®Google Scholar
• Luxembourger C, Ruyssen-Witrand A, Ladhari C, et al. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. Pharmacogenomics J. 2019;19(4):368–374.
   PubMed Web of Science ®Google Scholar
• Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, et al. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharmacogenomics J. 2018;18(1):167–172.
   PubMed Web of Science ®Google Scholar
• Gremese E, Cingolani A, Bosello SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020;27:100553.
   PubMedGoogle Scholar
• Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–1285.
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331.
   PubMedGoogle Scholar
• Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci USA. 2008;105(22):7809–7814.
   PubMed Web of Science ®Google Scholar
• Wang W, Ye L, Ye L, et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-Coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res. 2007;128(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: what treatments are being investigated? BMJ. 2020;368:m1252.
   PubMedGoogle Scholar
• Robinson PC, Liew DFL, Liew JW, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med. 2020;1(1):90–102.
   Google Scholar
• Robinson PC, Richards D, Tanner HL, et al. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2(11):e653–e655.
   PubMedGoogle Scholar
• Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407–1409.
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Krishnan V, Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):2020697.
   Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Sorrell Fiona J, Szklarz M, Abdul Azeez Kamal R, et al. Family-wide structural analysis of human numb-associated protein kinases. Structure. 2016;24(3):401–411.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Deftereos SG, Siasos G, Giannopoulos G, et al. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol. 2020;61(1):42–45.
   PubMed Web of Science ®Google Scholar
• Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):175–180.
   PubMed Web of Science ®Google Scholar
• Décary S, Barton JL, Proulx L, et al. How to effectively support patients with rheumatic conditions now and beyond COVID-19. ACR Open Rheuma. 2020;2(9):505–506.
   PubMedGoogle Scholar
• Zhang Y, Wang J, Zhao L, et al. Online management of rheumatoid arthritis during COVID-19 pandemic. Ann Rheum Dis. 2021;80(1):e4–e4.
   PubMed Web of Science ®Google Scholar
• McInnes IB. COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis. 2020;79(5):551–552.
   PubMed Web of Science ®Google Scholar